Katherine Podraza, MD
Pain Medicine · Mystic, CTNPI 1457731986
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,663 of the $8,273 with a category attached, or 80.5%. AbbVie accounts for 88.6% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $7,257, more than ten times the $125 reported in 2019.
Across 76 payments — averaging $108.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$7K
- Pfizer$279
- Lundbeck LLC$229
- Amgen$125
- EMD Serono, Inc.$89
- Johnson & Johnson$40
- plus $182 from 7 others
Across 1 payment — averaging $75,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$75K
What the payments were for
- Speaking & faculty fees$6,66381%
- Food & beverage$1,61019%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 33 | $7,328 |
| Pfizer | 14 | $279 |
| Lundbeck LLC | 15 | $229 |
| Amgen | 1 | $125 |
| EMD Serono, Inc. | 5 | $89 |
| Johnson & Johnson | 1 | $40 |
| UCB, Inc. | 1 | $35 |
| Vanda Pharmaceuticals Inc. | 1 | $31 |
| Eisai Inc. | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Genentech USA, Inc. | 1 | $25 |
| Scilex Pharmaceuticals Inc. | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,273 in reported general payments places this provider in the 80th percentile of 69 pain medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 109 | $153,148 |
| UbrelvyUbrogepant | 82 | $115,626 |
| Emgality PenGalcanezumab-Gnlm | 82 | $87,305 |
| QuliptaAtogepant | 61 | $75,218 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 51 | $49,896 |
| ZavzpretZavegepant Hcl | 20 | $22,010 |
| BotoxOnabotulinumtoxina | 14 | $18,579 |
| Aimovig AutoinjectorErenumab-Aooe | 16 | $16,295 |
| Memantine Hcl | 40 | $799 |
| Naratriptan Hcl | 23 | $601 |
| Topiramate | 49 | $590 |
| Oxcarbazepine | 11 | $568 |
| RizatriptanRizatriptan Benzoate | 29 | $506 |
| Pregabalin | 17 | $386 |
| Memantine Hcl ErMemantine Hcl | 14 | $362 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta, Botox | $7,328 | $209,423157 claims |
| PfizerNurtec Odt, Zavzpret | $279 | $175,157129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 69 pain medicine providers in Connecticut.
Other pain medicine in Mystic
- Sandeep JoharWaterbury$329K
- David GutierrezNew Haven$151K
- Brian GrosbergWest Hartford$99K
- Ofer WellischStamford$18K
- Yili HuangNew Haven$18K
- Jared RosenbergGreenwich$12K
- Sandhya MehlaWest Hartford$12K
- Hans KnoppMiddlebury$11K
- Daniel HaddadNew Haven$10K
- Rahul AnandFairfield$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.